March 2025 Quarterly Activities Report & Appendix 4C
Released
Released
Announcement PDF
ASX RELEASE
29 April 2025
March 2025 Quarterly Activities Report & Appendix 4C
Key Highlights
•
Ethics Approval: Secured centralised HREC approval in Australia, enabling multisite phase 3 trial launch. First patient dosing remains on track for Q2 CY2025.
•
CRO Appointment: Advanced Clinical selected as CRO following rigorous selection
process, supporting global execution of phase 3.
•
R&D Refund: $6.3 million received under the FY24 R&D Tax Incentive scheme.
•
Cash Position: Cash balance of $24.56m as of 31 March, with expected inflows and
forecast outflows in line with commencement of trial execution.
•
Loyalty Program: Launch of Loyalty and Piggyback Option Offers to reward
shareholders and potentially raise over $110 million in follow-on capital.
Paradigm Biopharmaceuticals Ltd. (ASX: PAR) (“Paradigm” or “the Company”) is
pleased to provide its quarterly update for the three months ended 31 March 2025 and
continuing activities to accompany its Appendix 4C cash flow report for the period.
Operational Update
Paradigm has advanced critical regulatory and operational activities in preparation for its
global pivotal phase 3 trial evaluating injectable Pentosan Polysulfate Sodium (iPPS) in
knee osteoarthritis (OA).
In October, the updated phase 3 protocol (PARA_OA_012) was submitted to the US FDA
and reviewed without further queries, clearing the way for trial initiation. The study
(NCT06917404) is now live on the ClinicalTrials.gov registry.
Trial Design Overview
The trial is a global, randomised, double-blind, placebo-controlled study of 466 patients (1:1
randomisation). Participants will receive 12 subcutaneous doses of iPPS over six weeks,
administered twice weekly from Day 1 to Day 39.
•
Primary Endpoint: Change from baseline in average daily pain score at Day 112,
measured via patient diaries to reduce recall bias and variability.
•
Key Secondary Endpoints:
o
WOMAC pain and function scores through Day 404
o
Patient Global Impression of Change (PGIC)
o
OARSI responder rate
o
Paracetamol (rescue medication) usage
The trial also incorporates MRI and X-ray imaging over a 12-month follow-up as secondary
endpoints to assess potential structural (disease-modifying) effects of iPPS.
Eligibility Criteria: Adults with Kellgren-Lawrence Grade 2–4 (moderate to severe) knee
OA and ≥ 6 months of chronic knee pain.
The study design incorporates insights from Paradigm’s phase 2 program and investigatorled studies by Ghosh and Kumagai and reflects feedback from the FDA to align with
regulatory expectations for a registration-directed trial.
Operational Progress
Paradigm is actively mitigating placebo response through standardised diary-based pain
assessments and rigorous staff training.
•
Australia: ~10 clinical sites (Melbourne, Sydney, Adelaide, Perth, Brisbane, Gold
Coast) are undergoing activation, with enrolment and dosing set to begin in May
2025 (Q2 CY2025). Centralised ethics approval was secured in February 2025 to
accelerate site onboarding.
•
United States Sites: Site start-up activities are expected to begin in Q3 CY2025,
ultimately targeting 60 centres across the US and Australia.
Interim Analysis
An interim analysis, led by an independent Data Safety Monitoring Board (DSMB), will occur
after 50% of participants reach the Day 112 endpoint. This analysis, planned for mid-2026,
includes predefined efficacy thresholds that may support early termination of the study.
Trial Management
Advanced Clinical was appointed as the global CRO during the quarter, selected for its
expertise in osteoarthritis trials and patient-centric trial execution.
Paradigm is targeting 50% patient recruitment by end-CY2025, keeping the program on
track for interim analysis by mid-CY2026.
Conference and Investor Engagement
During the quarter, Paradigm participated in the Bell Potter Horizon Biotech Summit held
in Sorrento, Victoria. The event provided senior management with an opportunity to
contribute to panel discussions alongside other leading Australian biotech companies and
to engage in one-on-one meetings with institutional investors.
Paradigm also attended the Ignite Investor Summit in Hong Kong from 22–24 March 2025.
Managing Director Paul Rennie delivered a company presentation highlighting clinical and
corporate progress and met with both existing and prospective investors.
Additionally, Dr Donna Skerrett presented at the NWR Healthcare Conference, delivering
an overview of the PARA_OA_012 Phase 3 clinical trial and sharing results from multiple
prior Phase 2 studies. These studies continue to support confidence in iPPS as a potential
treatment for osteoarthritis. The full presentation, including Q&A, is available on the
Paradigm website.
Financial Highlights
Cash and cash equivalents as at 31 March 2025 were $24.56m. Paradigm’s cash spending
for the March 2025 quarter was $6.49m, which was $5.51m below the forecast $12 million.
As at 31 March, the company had approximately $600k in Invoices to be paid in relation to
phase 3 startup activities.
In January, Paradigm received a $6.3 million refund under the FY24 R&D Tax Incentive
program, enhancing its runway.
To reward long-term holders, during the March 2025 quarter, Paradigm launched a Loyalty
Option Offer (1 option for every 4 shares held) with an exercise price of $0.65 and 12-month
expiry (February 2026). For every 2 Loyalty Options exercised, shareholders receive 1
Piggyback Option exercisable at $1.00, expiring February 2028. If fully subscribed and
exercised, the program could raise up to $111.9 million.
Paul Rennie, MD of Paradigm Biopharma, commented on the quarter:
"This quarter for Paradigm we have successfully transitioned from regulatory clearance into
trial execution. Despite a challenging macroeconomic backdrop for biotech, with funding
uncertainty in global research institutions, shifting sentiment in Washington, and structural
changes within the FDA, we are pleased with our ability to maintain momentum. We now
enter the June quarter with clear line of sight to multiple operational milestones, including
site activation, first patient enrolment, and dosing in Australia.
As we move forward, we are energised by the robust data we've consistently demonstrated
across previous Phase 2 trials and the real-world evidence base built through hundreds of
patient experiences with iPPS. Our team remains focused on disciplined execution and
maintaining the trust of our shareholders, whose continued belief in the therapeutic
potential of iPPS is both acknowledged and deeply appreciated."
Summary of Cash Flow and Quarterly Activity
As of 31 March 2025, Paradigm's cash and cash equivalents totalled $24.56m (on 31
December 2024 it was $24.78m). The net cash outflow for the March 2025 quarter was
$121k.The company continues to prioritise resource allocation towards the advancement
of its pivotal phase 3 clinical trial for osteoarthritis.
•
During the March quarter, Paradigm allocated $5.37m towards research and
development activities. Key areas of expenditure included the submission of ethics
applications in Australia, site preparation activities, and procurement of clinical trial
materials to support the execution of the phase 3 trial locally. These investments
reflect Paradigm’s continued focus on progressing the Australian arm of the study
in alignment with the broader global trial timeline.
•
Paradigm continues to explore strategic funding opportunities, including
partnerships or licensing agreements, to materially extend the company’s cash
runway in support of its phase 3 program. The company has a defined timeline for
patient recruitment and site activation, including commencement of US operations,
and is well advanced in discussions to secure the necessary capital to support these
activities and accelerate commercialisation efforts.
•
During the March quarter, Paradigm received a $6.3 million rebate under the R&D
Tax Incentive scheme. These funds will be directed toward ongoing phase 3 clinical
trial operations in Australia, which are expected to continue qualifying for future R&D
rebates.
•
Paradigm expects a cash outflow of approximately $10–12 million for the June 2025
quarter, primarily driven by clinical site activations, patient recruitment for the Phase
3 trial, and ongoing operational expenses to support trial activities.
•
In accordance with Listing Rule 4.7C.3 and as noted in item 6 of the Appendix 4C
Cashflow Statement, payments to related parties and their associates during the
quarter totalled $47K, covering $40K in non-executive Director fees and $7K for
legal fees to BioMeltzer, an entity controlled by Amos Meltzer.
OUTLOOK
Phase 3 Trial Launch
Paradigm enters the March 2025 quarter with a strong operational focus on initiating its
Australian Phase 3 activities. The Company anticipates activating the first clinical trial sites,
enrolling the first subject, and commencing dosing—all within the quarter. This progression
marks the formal transition from pre-trial preparation to active patient engagement in
Australia. These milestones are critical as they represent the beginning of clinical execution
for PARA_OA_012 and form the foundation for broader global activation throughout 2025.
Manuscript Submissions
Editor feedback for two manuscripts based on Paradigm’s Phase 2 osteoarthritis (OA)
clinical data has been received from their respective journals. Paradigm is working closely
with the authors to address the requested revisions, and both manuscripts have now been
resubmitted for further editorial consideration.
The manuscripts are as follows:
•
PARA_OA_008 Phase 2 Clinical Trial Results Manuscript – detailing the
outcomes of the Phase 2 study, with updates made to support progression through
the peer review process.
•
iPPS Comparison Manuscript – presenting a comparative analysis of
PARA_OA_008 data against existing and emerging OA treatments.
Both manuscripts remain under editorial review. Paradigm expects to update the market
once timelines for acceptance and publication become available.
Upcoming Milestones
•
Peer Review Publications: Two publications from the PARA_OA_008 Phase 2
study are currently under review. One focuses on efficacy outcomes, while the other
provides a comparative analysis of the osteoarthritis treatment landscape.
•
First Patient Enrolment (Australia): First participant enrolment in the
PARA_OA_012 Phase 3 trial is expected in Q2 CY2025.
•
First Patient Enrolment (US): Enrolment of the first US participant is forecast for
the second half of CY2025.
•
50% Recruitment Milestone: Paradigm expects to achieve 50% participant
recruitment by end- CY2025, at which point interim analysis preparations will
commence.
•
Interim Analysis: Interim data readout anticipated in mid-CY2026.
•
Full Recruitment Completion: Full participant recruitment for the PARA_OA_012
study is targeted for H1 CY2026.
About Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. (ASX: PAR) is a late-stage drug development company
driven by a purpose to improve patients’ health and quality of life by discovering,
developing, and delivering pharmaceutical therapies. Paradigm’s current focus is
developing iPPS for the treatment of diseases where inflammation plays a major
pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative
properties of PPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase
2).
Forward Looking Statements
This Company announcement contains forward-looking statements, including statements
regarding anticipated commencement dates or completions dates of preclinical or clinical
trials, regulatory developments, and regulatory approval. These forward-looking
statements are not guarantees or predictions of future performance, and involve known
and unknown risks, uncertainties, and other factors, many of which are beyond our control,
and which may cause actual results to differ materially from those expressed in the
statements contained in this presentation. Readers are cautioned not to put undue reliance
on forward-looking statements.
Authorised for release by the Paradigm Board of Directors.
FOR FURTHER INFORMATION PLEASE CONTACT:
Simon White
Director of Investor Relations
Tel: +61 404 216 467
Paradigm Biopharmaceuticals Ltd.
ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
Email: investorrelations@paradigmbiopharma.com
Paradigm Biopharma
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Paradigm Biopharmaceuticals Limited
ABN
Quarter ended (“current quarter”)
94 169 346 963
31 March 2025
Consolidated statement of cash flows
Current quarter
$A’000
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Year to date (9
months)
$A’000
-
41
(5,468)
(11,676)
(b) product manufacturing and operating
costs
-
-
(c) advertising and marketing
-
(51)
(d) leased assets
(18)
(66)
(e) staff costs
(458)
(1510)
(f)
(584)
(1,569)
-
-
(a) research and development
administration and corporate costs
1.3
Dividends received (see note 3)
1.4
Interest received
109
197
1.5
Interest and other costs of finance paid
(2)
(6)
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
6,300
6,300
1.8
Other (provide details if material)
-
-
1.9
Net cash from / (used in) operating
activities
(121)
(8,341)
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
other non-current assets
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
2.2
Current quarter
$A’000
Year to date (9
months)
$A’000
Proceeds from disposal of:
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
other non-current assets
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
-
-
2.6
Net cash from / (used in) investing
activities
-
-
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
-
16,000
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
1
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
(57)
(882)
-
-
(13)
(71)
3.2
3.5
Proceeds from borrowings
3.6
Repayment of borrowings (lease liabilities)
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
-
-
3.9
Other (Limited recourse loan repaid under
ESP)
-
-
3.10
Net cash from / (used in) financing
activities
(70)
15,048
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
24,778
17,867
(121)
(8,341)
-
-
4.2
4.3
Net cash from / (used in) operating
activities (item 1.9 above)
Net cash from / (used in) investing activities
(item 2.6 above)
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
Current quarter
$A’000
Year to date (9
months)
$A’000
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
(70)
15,048
4.5
Effect of movement in exchange rates on
cash held
(27)
(14)
4.6
Cash and cash equivalents at end of
period
24,560
24,560
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
5.2
Call deposits
5.3
Bank overdrafts
5.4
Other (provide details)
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
24,560
24,778
24,560
24,778
Current quarter
$A'000
47
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
7.1
Loan facilities
-
-
7.2
Credit standby arrangements
-
-
7.3
Other (please specify)
-
-
7.4
Total financing facilities
-
-
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
8.
Estimated cash available for future operating activities
8.1
Net cash from / (used in) operating activities (item 1.9)
(122)
8.2
Cash and cash equivalents at quarter end (item 4.6)
24,560
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
-
$A’000
24,560
201
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer:.
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer:
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer:
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
..29 April 2025.................................................................................
Authorised by: ...By the board................................................................................
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover